Organisation paid for research Program year 2025 Source: CMS Open Payments

St Louis University

Neither a doctor nor a teaching hospital

Research payments

$6,664,547

1,299 payments

Through program year 2025, St Louis University is reported as receiving $6,664,547 in research payments, across 1,299 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $1,544,463 238
2024 Research $1,113,701 192
2023 Research $929,727 194
2022 Research $1,139,421 177
2021 Research $645,024 142
2020 Research $563,567 163
2019 Research $728,643 193

Breakdown

Who paid Research payments · program years 2019–2025
  1. Regeneron Pharmaceuticals, Inc. $1,016,098 276 payments
  2. AbbVie, Inc. $694,487 123 payments
  3. Medtronic, Inc. $685,375 33 payments
  4. Sanofi Pasteur Inc. $567,869 22 payments
  5. Novartis Pharmaceuticals Corporation $525,707 12 payments
  6. Bavarian Nordic A/S $465,100 51 payments
  7. Gilead Sciences, Inc. $431,260 132 payments
  8. CSL Behring $232,245 24 payments
  9. Inari Medical, Inc. $230,570 177 payments
  10. ACADIA Pharmaceuticals Inc $179,467 19 payments
Studies the money was for Research payments · program years 2019–2025
  1. Expand II $685,375 33 payments
  2. An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients >=6 Months to <18 Years of Age With Atopic Dermatitis $598,688 184 payments
  3. Controlled Study of Immunogenicity and Safety of the Investigational vYF Candidate Vaccine in Comparison to YF-VAX in Adults $411,068 24 payments
  4. An Open-Label, Randomized, Phase III Study Comparing 177Lu-Psma-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (Mhspc) $402,869 3 payments
  5. A Study to the Assess the Change in Condition and Adverse Events of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines $238,446 10 payments
  6. A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Large Simple Trial Evaluating the Use of BE1116 (4-Factor Prothrombin Complex Concentrate [Kcentra / Beriplex]) to Improve Survival in Patients With Traumatic Injury and Acute Major Bleeding $219,283 21 payments
  7. A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age $213,346 39 payments
  8. Study on an Investigational Yellow Fever Vaccine Compared With YF-VAX in Adults in the USA $153,656 1 payment
  9. An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients 6 Months to 18 Years of Age With Atopic Dermatitis $140,347 25 payments
  10. Nct05238025 $136,198 9 payments
What the money was spent on Research payments · program years 2019–2025
  1. Patient care $51,254 4 payments
  2. Other $18,733 7 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record